Brainstorm Cell Therapeutics Inc banner

Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI

Watchlist Manager
Brainstorm Cell Therapeutics Inc Logo
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Watchlist
Price: 0.56 USD -4.03% Market Closed
Market Cap: $6.2m

During the last 3 months Brainstorm Cell Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 16% over this period (open performance analysis).

The last transaction was made on Oct 1, 2024 by Lebovits Chaim , who bought 6.3k USD worth of BCLI shares.

Last Transactions:
Lebovits Chaim
$+418.1
Lebovits Chaim
$+334.5
Dagher Ibrahim B.
$-1.5k
Lebovits Chaim
$+518.3
Lebovits Chaim
$+1.1k
Lebovits Chaim
$+965.2
Lebovits Chaim
$+326.8
Lebovits Chaim
$+311.2
Lebovits Chaim
$+619.8
Lebovits Chaim
$+1.7k
Lebovits Chaim
$+3.4k
Lebovits Chaim
$+519.9
Lebovits Chaim
$+4k
Lebovits Chaim
$+4.7k
Lindborg Stacy
$+1.4k
Lindborg Stacy
$+143k
Setboun David
$+4.3k
Acc International Holdings Ltd.
$-7k
Abbhi Sankesh
$+40.5k
Acc International Holdings Ltd.
$-16.1k
Acc International Holdings Ltd.
$-36.1k
Acc International Holdings Ltd.
$-1.8k
Acc International Holdings Ltd.
$-3.1k
Kern Ralph Dr.
$+776
Shah Preetam
$+3.1k
Araya Arturo
$+780
Arbel Irit
$-3.3k
Almenoff June Sherie
$+332.2
Arbel Irit
$+711.4
Yablonka Uri
$+529.3
Shorr Robert G L
$-2k
Taub Malcolm S
$-1.9k
View All Transactions

During the last 3 months Brainstorm Cell Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 16% over this period (open performance analysis).

The last transaction was made on Oct 1, 2024 by Lebovits Chaim , who bought 6.3k USD worth of BCLI shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Brainstorm Cell Therapeutics Inc
Insider Trading Chart

Brainstorm Cell Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Brainstorm Cell Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Brainstorm Cell Therapeutics Inc
Glance View

Market Cap
6.2m USD
Industry
Biotechnology

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.

BCLI Intrinsic Value
Not Available

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top